A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors
Clinical trial NCT02541604 · TERMINATED
Trial details
- NCT number
- NCT02541604
- Sponsor
- Hoffmann-La Roche
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-11-30
- Primary completion
- 2019-06-06
- Enrollment
- 87
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.